Literature DB >> 28477547

Plasma and cerebrospinal fluid G72 protein levels in schizophrenia and major depressive disorder.

Sayuri Ishiwata1, Kotaro Hattori2, Daimei Sasayama3, Toshiya Teraishi3, Tomoko Miyakawa4, Yuuki Yokota4, Ryo Matsumura4, Fuyuko Yoshida3, Toru Nishikawa5, Hiroshi Kunugi6.   

Abstract

G72 is a modulator of D-amino acid oxidase, the enzyme that degrades D-serine, an amino acid that plays a critical role in glutamate neurotransmission, and has been implicated in psychiatric disorders. The aim of this study was to examine whether plasma or cerebrospinal fluid (CSF) G72 protein levels were altered in either schizophrenia or major depressive disorder (MDD) and whether any correlation between G72 levels and disease severity existed. Initially, 27 schizophrenic patients, 26 MDD patients, and 27 healthy controls matched for age, sex, and ethnicity were enrolled. Compared to those of controls, plasma or CSF G72 levels were not significantly different in patients with schizophrenia or MDD. Although we found a significant positive correlation between plasma G72 levels and a positive symptoms score on the positive and negative syndrome scale (PANSS), this was not replicated in the second study (40 schizophrenic patients). CSF G72 levels showed no significant correlation with PANSS scores. In MDD, neither plasma nor CSF G72 levels correlated significantly with depression severity. Since severity of our patients were relatively mild, further investigations in a large number of subjects including drug-free patients, younger patients, and more severely affected patients are warranted.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28477547     DOI: 10.1016/j.psychres.2017.04.060

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  5 in total

Review 1.  d-Amino Acids and pLG72 in Alzheimer's Disease and Schizophrenia.

Authors:  Yu-Jung Cheng; Chieh-Hsin Lin; Hsien-Yuan Lane
Journal:  Int J Mol Sci       Date:  2021-10-09       Impact factor: 5.923

2.  Consensus on potential biomarkers developed for use in clinical tests for schizophrenia.

Authors:  Ping Lin; Junyu Sun; Xiaoyan Lou; Dan Li; Yun Shi; Zhenhua Li; Peijun Ma; Ping Li; Shuzi Chen; Weifeng Jin; Shuai Liu; Qing Chen; Qiong Gao; Lili Zhu; Jie Xu; Mengyuan Zhu; Mengxia Wang; Kangyi Liang; Ling Zhao; Huabin Xu; Ke Dong; Qingtian Li; Xunjia Cheng; Jinghong Chen; Xiaokui Guo
Journal:  Gen Psychiatr       Date:  2022-02-23

Review 3.  D-Amino Acids as a Biomarker in Schizophrenia.

Authors:  Kurumi Taniguchi; Haruka Sawamura; Yuka Ikeda; Ai Tsuji; Yasuko Kitagishi; Satoru Matsuda
Journal:  Diseases       Date:  2022-01-31

Review 4.  Biochemical Properties and Physiological Functions of pLG72: Twenty Years of Investigations.

Authors:  Giulia Murtas; Loredano Pollegioni; Gianluca Molla; Silvia Sacchi
Journal:  Biomolecules       Date:  2022-06-20

5.  The role of trauma experiences, personality traits, and genotype in maintaining posttraumatic stress disorder symptoms among child survivors of the Wenchuan earthquake.

Authors:  Yuwei Li; Qiuyue Lv; Bin Li; Dan Luo; Xueli Sun; Jiajun Xu
Journal:  BMC Psychiatry       Date:  2020-09-07       Impact factor: 3.630

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.